MicroRNAs and Long Non-coding RNAs in C-Met-Regulated Cancers

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2020 Mar 29

PMID 32219093

Citations 15

Authors

Hong Zhan

Sheng Tu

Feng Zhang

Anwen Shao

Jun Lin

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are components of many signaling pathways associated with tumor aggressiveness and cancer metastasis. Some lncRNAs are classified as competitive endogenous RNAs (ceRNAs) that bind to specific miRNAs to prevent interaction with target mRNAs. Studies have shown that the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/c-Met) pathway is involved in physiological and pathological processes such as cell growth, angiogenesis, and embryogenesis. Overexpression of c-Met can lead to sustained activation of downstream signals, resulting in carcinogenesis, metastasis, and resistance to targeted therapies. In this review, we evaluated the effects of anti-oncogenic and oncogenic non-coding RNAs (ncRNAs) on c-Met, and the interactions among lncRNAs, miRNAs, and c-Met in cancer using clinical and tissue chromatin immunoprecipition (ChIP) analysis data. We summarized current knowledge of the mechanisms and effects of the lncRNAs/miR-34a/c-Met axis in various tumor types, and evaluated the potential therapeutic value of lncRNAs and/or miRNAs targeted to c-Met on drug-resistance. Furthermore, we discussed the functions of lncRNAs and miRNAs in c-Met-related carcinogenesis and potential therapeutic strategies.

Citing Articles

Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies.

Iweala E, Amuji D, Oluwajembola A, Ugbogu E Curr Res Pharmacol Drug Discov. 2024; 7:100204.

PMID: 39524211 PMC: 11543557. DOI: 10.1016/j.crphar.2024.100204.

Management of triple-negative breast cancer by natural compounds through different mechanistic pathways.

Kaleem M, Thool M, Dumore N, Abdulrahman A, Ahmad W, Almostadi A Front Genet. 2024; 15:1440430.

PMID: 39130753 PMC: 11310065. DOI: 10.3389/fgene.2024.1440430.

lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways.

Saleh R, Al-Ouqaili M, Ali E, Alhajlah S, Kareem A, Shakir M Med Oncol. 2024; 41(2):52.

PMID: 38195957 DOI: 10.1007/s12032-023-02263-8.

MET overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: A signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs.

Kwon J, Jang Y, Yun B, Kang S, Kim Y, Kim B Cell Prolif. 2023; 57(5):e13582.

PMID: 38030594 PMC: 11056702. DOI: 10.1111/cpr.13582.

Virus-like nanoparticles as a theranostic platform for cancer.

Kim K, Lee A, Kim S, Heo H, Kim C Front Bioeng Biotechnol. 2023; 10:1106767.

PMID: 36714624 PMC: 9878189. DOI: 10.3389/fbioe.2022.1106767.

References

Wan L, Zhu L, Xu J, Lu B, Yang Y, Liu F . MicroRNA-409-3p functions as a tumor suppressor in human lung adenocarcinoma by targeting c-Met. Cell Physiol Biochem. 2014; 34(4):1273-90. DOI: 10.1159/000366337. View

Di Martino M, Campani V, Misso G, Gallo Cantafio M, Gulla A, Foresta U . In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One. 2014; 9(2):e90005. PMC: 3937395. DOI: 10.1371/journal.pone.0090005. View

Hwang C, Matoso A, Corney D, Flesken-Nikitin A, Korner S, Wang W . Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A. 2011; 108(34):14240-5. PMC: 3161601. DOI: 10.1073/pnas.1017536108. View

Chen Q, Jiao D, Yan L, Wu Y, Hu H, Song J . Comprehensive gene and microRNA expression profiling reveals miR-206 inhibits MET in lung cancer metastasis. Mol Biosyst. 2015; 11(8):2290-302. DOI: 10.1039/c4mb00734d. View

Zhu L, Xue F, Xu X, Xu J, Hu S, Liu S . MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer. J Cell Biochem. 2018; 119(9):7873-7886. DOI: 10.1002/jcb.27204. View

Cao X, Lai S, Hu F, Li G, Wang G, Luo X . miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met. Sci Rep. 2017; 7(1):2939. PMC: 5462753. DOI: 10.1038/s41598-017-01153-0. View

Long Z, Bai Z, Song J, Zheng Z, Li J, Zhang J . Inhibits Proliferation and Migration of Colorectal Cancer SW480 Cells. Anticancer Res. 2017; 37(8):4345-4352. DOI: 10.21873/anticanres.11828. View

Zhang Y, Schiff D, Park D, Abounader R . MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. PLoS One. 2014; 9(3):e91546. PMC: 3951453. DOI: 10.1371/journal.pone.0091546. View

Gao S, Zhao Z, Wu R, Wu L, Tian X, Zhang Z . MiR-1 inhibits prostate cancer PC3 cells proliferation through the Akt/mTOR signaling pathway by binding to c-Met. Biomed Pharmacother. 2018; 109:1406-1410. DOI: 10.1016/j.biopha.2018.10.098. View

10.

Zhu Y, Liang Z, Li S, Xu X, Wang X, Wu J . c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3β/Snail signaling. Cell Death Dis. 2016; 7:e2088. PMC: 4849142. DOI: 10.1038/cddis.2015.274. View

11.

Li S, Zhang H, Wang X, Qu Y, Duan J, Liu R . Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer. Tumour Biol. 2016; 37(11):15175-15183. DOI: 10.1007/s13277-016-5390-6. View

12.

Salgia R . MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017; 16(4):555-565. DOI: 10.1158/1535-7163.MCT-16-0472. View

13.

Guo B, Zhang Q, Wang H, Chang P, Tao K . KCNQ1OT1 promotes melanoma growth and metastasis. Aging (Albany NY). 2018; 10(4):632-644. PMC: 5940105. DOI: 10.18632/aging.101418. View

14.

Barrow-McGee R, Kishi N, Joffre C, Menard L, Hervieu A, Bakhouche B . Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes. Nat Commun. 2016; 7:11942. PMC: 4931016. DOI: 10.1038/ncomms11942. View

15.

Sun Y, Zhao Y, Zhao X, Lee R, Teng L, Zhou C . Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation. Molecules. 2017; 22(10). PMC: 6158866. DOI: 10.3390/molecules22101724. View

16.

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H . The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-5. PMC: 3076220. DOI: 10.1038/nm.2284. View

17.

Wei B, Huang Q, Huang S, Mai W, Zhong X . MicroRNA‑34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET. Mol Med Rep. 2015; 12(4):5255-61. DOI: 10.3892/mmr.2015.4110. View

18.

Nasser M, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S . Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 2008; 283(48):33394-405. PMC: 2586284. DOI: 10.1074/jbc.M804788200. View

19.

Niu G, Li B, Sun J, Sun L . miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met. Cell Prolif. 2015; 48(3):348-55. PMC: 6496886. DOI: 10.1111/cpr.12187. View

20.

Koshizuka K, Hanazawa T, Fukumoto I, Kikkawa N, Matsushita R, Mataki H . Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma. J Hum Genet. 2016; 62(1):113-121. DOI: 10.1038/jhg.2016.47. View